Teleflex Incorporated

NYSE TFX

Teleflex Incorporated Price to Earnings Ratio (P/E) on January 14, 2025: 35.05

Teleflex Incorporated Price to Earnings Ratio (P/E) is 35.05 on January 14, 2025, a 8.54% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.
  • Teleflex Incorporated 52-week high Price to Earnings Ratio (P/E) is 48.82 on September 30, 2024, which is 39.30% above the current Price to Earnings Ratio (P/E).
  • Teleflex Incorporated 52-week low Price to Earnings Ratio (P/E) is 28.28 on March 15, 2024, which is -19.31% below the current Price to Earnings Ratio (P/E).
  • Teleflex Incorporated average Price to Earnings Ratio (P/E) for the last 52 weeks is 36.76.
Key data
Date Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield
Market news
Loading...
NYSE: TFX

Teleflex Incorporated

CEO Mr. Liam J. Kelly
IPO Date March 17, 1980
Location United States
Headquarters 550 East Swedesford Road
Employees 14,500
Sector Health Care
Industries
Description

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

Similar companies

HAE

Haemonetics Corporation

USD 79.96

0.69%

NVST

Envista Holdings Corp

USD 18.85

-0.74%

ATR

AptarGroup, Inc.

USD 154.61

0.47%

COO

The Cooper Companies, Inc.

USD 89.11

-2.38%

WST

West Pharmaceutical Services, Inc.

USD 328.96

-3.13%

BDX

Becton, Dickinson and Company

USD 235.80

-0.17%

RMD

ResMed Inc.

USD 228.83

-0.62%

MMSI

Merit Medical Systems, Inc.

USD 99.89

4.44%

ICUI

ICU Medical, Inc.

USD 161.08

1.85%

HOLX

Hologic, Inc.

USD 70.20

-0.13%

ANGO

AngioDynamics, Inc.

USD 11.80

-5.30%

StockViz Staff

January 15, 2025

Any question? Send us an email